Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
72,000
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,633.10 | 66.10 | 0.77% |
CAC 40 | 7,255.01 | 41.69 | 0.58% |
DAX 40 | 19,322.59 | 176.42 | 0.92% |
Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
FTSE 100 | 8,262.08 | 112.81 | 1.38% |
HKSE | 19,229.97 | 371.14 | -1.89% |
NASDAQ | 19,003.65 | 31.23 | 0.16% |
Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
S&P 500 | 5,969.34 | 20.63 | 0.35% |
S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
SSE Composite Index | 3,267.19 | 103.21 | -3.06% |